Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Behçet's disease

J D O'Duffy1

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905.

Current Opinion in Rheumatology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Behçet's disease diagnosis is improving, with new insights into arterial issues and T-cell roles. Research is focusing on better disease markers and refining immunosuppressive treatments for severe cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical images: The iron salute: a sign of hemochromatosis.

Arthritis and rheumatism·2011
Same author

Is there a place for large vessel disease in the diagnostic criteria of Behçet's disease?

The Journal of rheumatology·1999
Same author

Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy.

Neurology·1999
Same author

A study of the cutaneous manifestations of Behçet's disease in patients from the United States.

Journal of the American Academy of Dermatology·1999
Same author

Whipple's arthritis: direct detection of Tropheryma whippelii in synovial fluid and tissue.

Arthritis and rheumatism·1999
Same author

Improvement of myelopathy in Sjögren's syndrome with chlorambucil and prednisone therapy.

Neurology·1999
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Behçet's disease diagnosis relies on evolving criteria.
  • Previously underrecognized features like arterial aneurysms and phlebitis are now frequently reported.
  • These manifestations present treatment challenges, necessitating diverse therapeutic strategies.

Purpose of the Study:

  • To summarize current understanding and diagnostic trends for Behçet's disease.
  • To highlight emerging clinical features and their treatment implications.
  • To discuss advancements in identifying disease markers and therapeutic options.

Main Methods:

  • Review of international diagnostic criteria for Behçet's disease.
  • Analysis of recent clinical reports focusing on vascular manifestations.

Related Experiment Videos

  • Discussion of immunological findings, including T-lymphocyte subpopulations and function.
  • Exploration of genetic marker research, specifically HLA-B51.
  • Evaluation of current and novel immunosuppressive therapies.

    • Main Results:

    • International diagnostic criteria for Behçet's disease are gaining acceptance.
    • Arterial aneurysms and phlebitis are increasingly recognized clinical features.
    • T-lymphocyte abnormalities suggest a persistent immune response to an unknown antigen.
    • Research is actively seeking improved disease markers beyond HLA-B51.
    • Treatment choices for severe Behçet's disease involve balancing anticoagulation and immunosuppression.

    Conclusions:

    • Refinement of Behçet's disease diagnostic criteria is anticipated.
    • Understanding vascular involvement and T-cell dysfunction is crucial for management.
    • Targeted immunosuppressive therapies, including those inhibiting interleukin-2, are key for severe manifestations like uveitis and arteritis.